insulin lispro U200
Selected indexed studies
- Bioequivalence of Ultra Rapid Lispro (URLi) U100 and U200 Formulations in Healthy Subjects. (Diabetes Ther, 2020) [PMID:32535742]
- High Concentration Insulin. (Indian J Endocrinol Metab, 2018) [PMID:29535954]
- Patient characteristics of insulin lispro 200 units/mL users in real world setting in Germany. (Curr Med Res Opin, 2020) [PMID:32845743]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Bioequivalence of Ultra Rapid Lispro (URLi) U100 and U200 Formulations in Healthy Subjects. (2020) pubmed
- High Concentration Insulin. (2018) pubmed
- Patient characteristics of insulin lispro 200 units/mL users in real world setting in Germany. (2020) pubmed
- Insulin: Making Sense of Current Options. (2016) pubmed
- A randomized, open-label, comparative, crossover trial on preference, efficacy, and safety profiles of lispro insulin u-100 versus concentrated lispro insulin u-200 in patients with type 2 diabetes mellitus: a possible contribution to greater treatment adherence. (2018) pubmed
- Switching to insulin lispro U-200 in a pregnant woman using a 780G advanced hybrid closed-loop led to a rapid improvement in glucose metrics. (2025) pubmed
- Biorelevant subcutaneous in vitro test predicts the release of human and fast acting insulin formulations. (2024) pubmed
- U-200 Humalog Insulin Now Available in United States. (2016) pubmed
- What is the role of concentrated insulin in diabetes management? (2016) pubmed
- Concentrated insulins: History and critical reappraisal. (2019) pubmed